Physician profile
Cornelius Robens
NPI 1538158688
$202,609.52
in general payments reported to CMS, 2019-2025
45 companies · $23K in 2025
The $23K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $16K · 2021: $41K · 2022: $44K · 2023: $15K · 2024: $29K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Food and Beverage: $4,369 · Travel and Lodging: $2,809 · Consulting Fee: $2,255 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,970.40 |
| Food and Beverage | $4,369.27 |
| Travel and Lodging | $2,808.77 |
| Consulting Fee | $2,255.00 |
| Education | $124.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $73,749.70 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $48,796.15 | 2019-2025 | Ubrelvy, Qulipta, Botox |
| Biogen, INC. | $22,602.31 | 2019-2025 | Tysabri, Vumerity |
| Emd Serono, INC. | $18,406.66 | 2019-2025 | Mavenclad |
| Genzyme Corporation | $14,422.78 | 2019-2025 | |
| Kyowa Kirin, INC. | $7,906.02 | 2019-2024 | Nourianz |
| Lundbeck LLC | $5,060.33 | 2019-2020 | |
| Acorda Therapeutics, INC | $4,153.89 | 2019-2023 | Inbrija |
| Boston Scientific Corporation | $1,569.99 | 2019-2025 | Vercise, General - Dbs |
| Argenx US, INC. | $1,425.33 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Allergan, INC. | $1,241.75 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $1,144.10 | 2020-2025 | Nuplazid |
| Ucb, INC. | $255.56 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Lilly USA, LLC | $231.79 | 2019-2025 | Kisunla, Amyvid, Emgality |
| E.R. Squibb & Sons, L.L.C. | $143.24 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cornelius Robens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.